PLOD3

Across TCGA pan-cancer cohorts, PLOD3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLOD3 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PLOD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLOD3 expression acts as an unfavorable survival marker.

LSCC, HNSC, and CCRCC are the cancer types where PLOD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.645	0.965	<.001	61	view →
HNSC	OS	Tertile	All	0.614	0.872	.004	40	view →
CCRCC	OS	Median	II,III,IV	0.228	0.979	.003	35	view →
PDAC	DFS	Tertile	All	0.299	0.483	.010	12	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	8	view →
UCEC	DFS	Median	All	0.787	0.925	.021	6	view →
GBM	DFS	Quartile	All	0.730	0.867	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLOD3–LSCC (OS)

Open the LSCC breakdown →